LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual oral presentation of data from the Company’s Phase 1/2 InSight extension trial of sepofarsen and live Q&A session at the Association for Research in Vision and Ophthalmology (ARVO) held May 1-7, 2021. This is an encore presentation of the InSight study data that was presented during the Expert Perspectives Call in July 2020. We expect to present new data from the InSight study in H2 2021.

See the original post:
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO)...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh